09/06/2026 US FDA approved a new every-eight week maintaince dosing option for Lilly’s lebrikizumab in moderate-to-severe atopic dermatitis US FDA accepted Takeda's application for Intravenous vedolizumab in Pediatric UC and CD US FDA approved a new every-eight week maintaince dosing option for Lilly’s lebrikizumab in moderate-to-severe atopic dermatitis (Ref) Eli lilly announced that the US FDA approved a regimen of one maintenance dose every eight weeks of a single injectio

23/03/2026 Gilead Sciences to acquire Ouro Medicines to advance first in class T cell engager program for autoimmune diseases Apogee Therapeutics announced Phase 2 results of zumilokibart in Moderate-to-Severe AD Galapagos and Gilead in advanced discussions to collaborate on advancing first in class T cell engager program for autoimmune diseases Kali Therapeutics announced a worldwide exclusive license agreement with Sanofi for KT501 for autoimmune diseases Gilead Sciences to